Document:

Exhibit
4.8

 

 

SECURITIES
SUBJECT HERETO HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR UNDER THE SECURITIES
LAWS OF ANY STATE OR OTHER JURISDICTION, AND NEITHER THE LIMITED LIABILITY COMPANY INTERESTS NOR ANY INTEREST THEREIN MAY BE OFFERED,
SOLD, PLEDGED, ASSIGNED, OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER
SUCH ACT AND APPLICABLE LAWS OR SOME OTHER EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF SUCH ACT AND APPLICABLE LAWS OR AN OPINION
OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

 

LIMITED LIABILITY COMPANY INTEREST

WARRANT TO PURCHASE INTERESTS OF

CANCER PREVENTION PHARMACEUTICALS, LLC

 

No. W-CPP-1

 

This certifies
that, for value received, The Arizona Board of Regents, on behalf of The University of Arizona (“University") or its
registered transferees ("Holder"), is entitled, subject to the terms and conditions set forth herein, at any time during
the Exercise Period (as defined below), but not thereafter, to subscribe for and purchase from Cancer Prevention Pharmaceutical,
LLC, a limited liability company organized under the laws of Arizona (the "Company") Three Hundred Thousand
(300,000) Class A Units of the Company (as defined in the
Operating Agreement of the Company) (the "Interests"), and as set forth on Exhibit A attached hereto, subject
to adjustment as provided in Section 7 below, (the "Warrant Interests") which, as of the date hereof, represent approximately
Five and 66/100 Percent (5.66%) of the outstanding Interests of the Company. The term "Warrant" as used herein
shall mean this Warrant and any warrant delivered in substitution or exchange therefor as provided herein.

 

1.           Term
of Warrant. Subject to the terms and conditions set forth herein, this Warrant shall be exercisable, in whole or in part, but
not for less than twenty-seven thousand (30,000) Interests at a time (or such lesser number of Interests which may then constitute
the maximum number purchasable, such number being subject to adjustment as provided in Section 7 below) from time to time during
the term hereof, commencing on the date hereof and ending at 5:00 p.m. Mountain Standard Time on the Seven (7) year anniversary
of the date of this Warrant (the "Exercise Period"), after which time this Warrant shall be void.

 

2.           Exercise
Price. The exercise price ("Exercise Price") of the Company's Interests covered by this Warrant shall be Ten
Cents ($0.10) each, as set forth on Exhibit A attached hereto. The Exercise Price and the number of Warrant Interests shall
be subject to adjustment as provided herein.

 

	

 

Arizona's First University -
Since 1885.

 

     

     

    

 

Exercise of Warrant.

 

(a)          Cash
Exercise. This Warrant may be exercised by Holder by (i) the surrender of this Warrant to the Company at the Company's address
given in Section 1l(e) below, with the Notice of Exercise attached hereto as Exhibit B duly executed on behalf of Holder, at the
office of the Company (or such other office or agency of the Company as the Company may designate by notice in writing to Holder
at the address of Holder appearing on the books of the Company) during the Exercise Period and (ii) the delivery of payment to
the Company, for the account of the Company, by cash, wire transfer of immediately available funds to a bank account specified
by the Company, or by certified or bank cashier's check, of the Exercise Price for the number of Warrant Interests specified in
the Notice of Exercise in lawful money of the United States of America. The Company agrees that such Warrant Interests shall be
deemed to be issued to Holder as the record holder of such Warrant Interests as of the close of business on the date on which this
Warrant is surrendered and payment made for the Warrant Interests in accordance with the provisions hereof, and the person entitled
to receive the Warrant Interests issuable upon such exercise shall be treated for all purposes as the holder of record of such
equity interests as of the close of business on such date. A certificate or certificates for the Warrant Interests specified in
the Notice of Exercise shall be delivered to Holder as promptly as practicable, and in any event within ten (10) days, thereafter.
If this Warrant is exercised only in part, then the Company shall,
at the time of delivery of the certificate or certificates, deliver to Holder a new Warrant evidencing the right to purchase the
remaining Warrant Interests, which new Warrant shall be identical to this Warrant in all other respects. Upon Holder's purchase
of all the Warrant Interests, the Company shall physically void the Warrant.

 

(b)          Net
Issue Exercise. Notwithstanding any provision herein to the contrary, if the Fair Market Value (as defined below) of one of
the Company's Interests is greater than the Exercise Price (at the date of calculation as set forth below), in lieu of exercising
this Warrant pursuant to Section 3(a) hereof, the Holder may elect to receive Interests equal to the value (as determined below)
of this Warrant (or portion thereof being canceled) by surrendering this Warrant to the Company, with a duly executed Notice of
Exercise marked to reflect Net Issue Exercise and specifying the number of Warrant Interests to be purchased, during normal business
hours on any business day during the Exercise Period. Such Warrant Interests shall be deemed to be issued to Holder as the record
holder of such Warrant Interests as of the close of business on the date on which this Warrant is surrendered in accordance with
the provisions hereof, and the person entitled to receive the Warrant Interests issuable upon such exercise shall be treated for
all purposes as the holder of record of such interests as of the close of business on such date. Upon such exercise, Holder shall
be entitled to receive, and the Company shall issue to Holder, a number of Warrant Interests computed as of
the date of surrender of this Warrant to the Company using the following formula:

 

X= Y (A-B)

A

 

	Where	X =	the number of Warrant Interests to be issued to Holder under this Section 3(b)
	 	 	 
	 	Y =	the number of Warrant Interests in respect of which this election is made;

 

     2

     

    

 

	 	A =	the Fair Market Value (as
    defined below) of one of the Company's Interests at the date of such calculation; and
	 	 	 
	 	B =	the Exercise Price (as adjusted to the date of the issuance).

 

(c)          Fair
Market Value. For the purposes of Section 3(b) hereof, the fair market value ("Fair Market Value") of one of the Company's
Interests shall mean, as of any date:

 

(i)          the
fair market value of one of the Company's Interests as of such date, as determined from the last closing price per interest of
the Company's Interests on the principal national securities exchange on which the Company's Interests are listed or admitted to
trading,

 

(ii)         .
the fair market value of one of the Company's Interests as of such date, as determined from the last reported sales price per interest
of the Company's Interests on the Nasdaq National Market or the Nasdaq Small-Cap Market (collectively, "Nasdaq")
if the Company's Interests are not listed or traded on any such exchange,

 

(iii)        the
fair market value of one of the Company's Interests as of such date, as determined from the average of the bid and asked price
per interest of the Company's Interests as reported in the "pink sheets" published by the National Quotation Bureau,
Inc. if the Company's Interests are not listed or traded on any exchange or Nasdaq, or

 

(iv)        if
such quotations are not available, the fair market value per interest of the Company's Interests on the date such notice was received
by the Company as determined in good faith by the Board of Directors of the Company; provided, however, that if the Warrant is
being exercised immediately prior to or upon the closing of an IPO (as defined in Section 9(e) below), the Fair Market Value shall
not be determined by the Board of Directors and shall be the initial "price to public" of one of the Company's Interests
specified in the final prospectus with respect to the IPO.

 

3.          No
Fractional Interests or Scrip. No fractional interests or scrip representing fractional interests shall be issued upon the exercise
of this Warrant. In lieu of any fractional interest to which Holder otherwise would be entitled, the Company shall make a cash
payment equal to the fair market value of one of the Company's Interests as determined under Section 3(c) multiplied by such fraction.

 

4.          Replacement
of Warrant. Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of
this Warrant and, in the case of loss, theft or destruction, upon delivery of a certification of loss (without obligation to indemnify)
by Holder reasonably satisfactory in form and substance to the Company or, in the case of mutilation, upon surrender and cancellation
of this Warrant, the Company at its expense shall execute and deliver, in lieu of this Warrant, a new warrant of like tenor and
amount.

 

     3

     

    

 

5.            No
Rights as a Member or Holder of Interests. Except as provided in this Section 6 (Subject to Sections 7 and 11 of this
Warrant), the Holder shall not be entitled to vote or be deemed a member or holder of Interests, nor shall anything contained
in this Warrant be construed to confer upon the Holder, as such, any of the rights of a member of the Company or any right to
vote for the election of managers or upon any matter submitted to members at any meeting thereof, or to give or withhold
consent to any company action (whether upon recapitalization, issuance of interests, reclassification of interests,
consolidation, merger, conveyance, or otherwise) or to receive notice of meetings, or to receive subscription rights or
otherwise until the Warrant shall have been exercised as provided herein. Nothing contained herein shall obligate Holder to
purchase any Company securities (upon exercise of this Warrant or otherwise).

 

6.            Adjustments.

 

(a)          Dividend,
Distribution, Subdivision or Split-Up. If, at any time after the date hereof, the number
of equity interests of the Company outstanding is increased by a dividend, distribution or by a subdivision or split-up of interests,
then, following the record date for the determination of holders of equity interests entitled to receive such dividend, distribution,
subdivision or split-up, the Exercise Price shall be appropriately decreased and the aggregate number of Warrant Interests shall
be increased in proportion to such increase in outstanding equity interests. The foregoing provisions shall similarly apply to
any successive dividend, distribution, subdivision or split-up.

 

(b)          Combination,
Reverse-Split. If, at any time after the date hereof, the number of equity interests of the Company outstanding is decreased
by a combination or reverse-split of equity interests, then, following the record date for the determination of holders of equity
interests for such combination or reverse-split, the Exercise Price shall be appropriately increased and the aggregate number of
Warrant Interests shall be decreased in proportion to such decrease in outstanding interests. The foregoing provisions shall similarly
apply to any successive combination or reverse-split.

 

(c)          Dividends
and Distributions. If, at any time after the date hereof, the holders of the securities as to which purchase rights under this
Warrant exist at the time shall have received, or, on or after the record date fixed for the determination of eligible members
or holders of interests, shall have become entitled to receive, without payment therefor, other or additional equity interests
or other securities or property (including cash) of the Company by way of a dividend or other distribution, then, and in each case,
this Warrant shall represent the right to acquire, in addition to the number of equity interests receivable upon exercise of this
Warrant, and without payment of any additional consideration therefor, the amount of such other or additional equity interests
or other securities or property (including cash) of the Company that such Holder would hold on the date of such exercise had it
been the holder of record of the equity interests receivable upon exercise of this Warrant on the date thereof and had thereafter,
during the period from the date thereof to and including the date of such event, retained such equity interests and/or all other
additional equity interests available to it during such period, all as adjusted pursuant to this Section 7.

 

(d)          Reorganization,
Reclassification, Consolidation, Merger or Asset Sale - Non- University Holder. With respect to any Holder other than University,
in the event of any capital reorganization of the Company, any reclassification of the equity interests of the Company (other than
as a result of a dividend, distribution or subdivision, split-up or combination of interests), any consolidation or merger of the
Company, or any sale of all or substantially all of the assets of the Company, this Warrant shall after such reorganization, reclassification,
consolidation, merger or asset sale be exercisable for the kind and number of equity interests or other securities, cash or property
of the Company or of the entity resulting from such reorganization, reclassification, consolidation, surviving such merger, or
such asset sale to which the Holder would have been entitled if this Warrant had been exercised immediately prior to the consummation
of such reorganization, reclassification, consolidation, merger or asset sale. The foregoing provisions shall similarly apply to
any successive reorganization, reclassification, consolidation, merger or asset sale.

 

     4

     

    

 

(e)          Reorganization,
Reclassification, Consolidation, Merger or Asset Sale - University Holder. With respect to University as Holder of this Warrant,
in the event of any capital reorganization of the Company, any reclassification of the equity interests of the Company (other than
as a result of a dividend, distribution or subdivision, split-up or combination of interests), any consolidation or merger of the
Company, or any sale of all or substantially all of the assets of the Company, immediately prior to the consummation of such reorganization,
reclassification, consolidation, merger or asset sale, regardless of the consideration provided for in such reorganization, reclassification,
consolidation, merger or asset sale (whether it be equity interests or other securities, debt, cash or property of the Company
or of the entity resulting from such reorganization, reclassification, consolidation, surviving such merger, or such asset sale),
at University's election (the "University Election"), the Company shall pay to University, in lieu of University exercising
this Warrant, in cash or cash equivalents, the aggregate value of the Warrant Interests as if this Warrant had been exercised immediately
prior to the consummation of such reorganization, reclassification, consolidation, merger or asset sale pursuant to Section 3(b),
where Fair Market Value is the price per fully-diluted Interest payable in such transaction. Such payment shall be made at the
closing of the transaction to which it relates. The foregoing provisions shall similarly apply to any successive reorganization,
reclassification, consolidation, merger or asset sale if University did not make the University Election and instead continued
to own the Warrant.

 

(f)          Calculations.
All calculations under this Section 7 shall be made to the nearest one hundredth (1/100) of a cent or the nearest one tenth (1110)
of an equity interest, as the case

may be.

 

(g)          No
Impairment. The Company will not, by any voluntary action, avoid or seek to avoid the observance or performance of any of the
terms of this Warrant to be observed or performed by the Company, but will at all times in good faith assist in the carrying out
of all the provisions of this Section 7 and in the taking of all such action as may be necessary or appropriate in order to protect
the rights of the Holder of this Warrant against impairment.

 

7.           Representations,
Warranties and Covenants. The Company represents, warrants and covenants to the Holder that (a) all of the Company's Interests
which may be issued upon the exercise of this Warrant will be, when issued, non-assessable, fully paid, and validly issued, with
no personal liability attaching to the ownership thereof, and free from all taxes, liens and charges created by the Company with
respect to the issue thereof and (b) the issuance of this Warrant, the Company's Interests issuable hereunder and the other transactions
contemplated hereunder do not require the consent of any person or entity and do not and shall not conflict, result in a default
under or violate the terms of the Company's articles of organization, operating agreement, or any other agreement, contract, document,
instrument or obligation which may be binding upon the Company. The Company further covenants and agrees that it will take all
such action as may be required to assure that the Company shall at all times have authorized and reserved, free from preemptive
rights, a sufficient number of the Company's Interests to provide for the exercise by Holder of all its rights with respect to
this Warrant. The Company agrees that its issuance of this Warrant shall constitute full authority to its officers who are charged
with the duty of executing certificates to execute and issue the necessary certificates for Company Interests upon the exercise
of this Warrant.

 

     5

     

    

 

8.            Transfer
of Warrant.

 

(a)          Transferability.
This Warrant may not be transferred or assigned in whole or in part without compliance with all applicable federal and state securities
laws by the transferor and the transferee (including the delivery of investment representation letters and legal opinions reasonably
satisfactory to the Company, if such are requested by the Company). Notwithstanding the foregoing, no investment representation
letter or opinion of counsel shall be required for any transfer of this Warrant (or any portion thereof) or of any of the Company's
Interests issued upon exercise hereof or conversion thereof (i) in compliance with Rule 144 or Rule 144A of the Act, or (ii) by
gift, will or intestate succession by Holder to his or her spouse or lineal descendants or ancestors or any trust for any of the
foregoing; provided that in each of the foregoing cases the transferee agrees in writing to be subject to the terms of this Warrant.
Subject to the provisions of this Warrant with respect to compliance with the Act, title to this Warrant may be transferred by
endorsement, in whole or in part, (by Holder executing the Assignment Form attached hereto as Exhibit C) and delivery in the same
manner as a negotiable instrument transferable by endorsement and delivery; provided, however, that in connection with any such
transfer any subsequent Holder will give the Company notice of the portion of the Warrant being transferred with the name, address,
and taxpayer identification number of the transferee and Holder will surrender this Warrant to the Company for reissuance to the
transferee(s) (and Holder if applicable). The Company may refuse to transfer this Warrant or the Warrant Interests to any person
who directly competes with the Company, unless, in either case, the equity interests of the Company are publicly traded.

 

(b)          Exchange
of Warrant Upon a Transfer. Upon surrender of this Warrant for exchange, properly endorsed on the Assignment Form attached
hereto as Exhibit C and subject to the provisions of this Warrant with respect to compliance with the Act and with the limitations
on assignments and transfers contained in this Section, the Company at its expense shall issue to, or upon the order of, Holder
a new warrant or warrants of like tenor, in the name of Holder or as Holder (upon payment by Holder of all applicable transfer
taxes, if any) may direct, for the number of equity interests issuable upon exercise hereof.

 

(c)          Further
Compliance with Securities Laws.

 

(i)          Holder,
by acceptance hereof, acknowledges that this Warrant and the Warrant Interests to be issued upon exercise hereof are being acquired
solely for Holder's own account and not as a nominee for any other party, and for investment, and that Holder will not offer, sell
or otherwise dispose of this Warrant or the Warrant Interests except under circumstances that will not result in a violation of
the Act or applicable state securities laws. Upon exercise of this Warrant, Holder shall confirm in writing, in a form satisfactory
to the Company, that the Warrant Interests so purchased are being acquired solely for Holder's own account and not as a nominee
for any other party, for investment, and not with a view toward distribution or resale.

 

     6

     

    

 

(ii)         This
Warrant and all Warrant Interests issued upon exercise hereof shall be stamped or imprinted with a legend in substantially the
following form (in addition to any legend required by applicable state securities laws):

 

SECURITIES
SUBJECT HERETO HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR UNDER THE SECURITIES
LAWS OF ANY STATE OR OTHER JURISDICTION, AND NEITHER THE LIMITED LIABILITY COMPANY INTERESTS NOR ANY INTEREST THEREIN MAY BE OFFERED,
SOLD, PLEDGED, ASSIGNED, OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER
SUCH ACT AND APPLICABLE LAWS OR SOME OTHER EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF SUCH ACT AND APPLICABLE LAWS OR AN OPINION
OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

 

(d)          Removal
of Legend. The Company agrees to remove promptly, upon the request of the Holder of this Warrant and securities issuable upon
exercise of the Warrant, the foregoing legend from the documents and/or certificates representing such securities upon full compliance
with the terms and provisions hereof and Rules 144 and 145 under the Act.

 

(e)          Lock-Up
Agreement. Holder shall not, without the prior written consent of the Company's governing body (such as its Board of Directors)
in its sole discretion, offer or sell this Warrant or any. of the Warrant Interests for one hundred eighty (180) days after the
closing of an initial public offering of the Company's Interests under the Act, the result of which is that the Company's Interests
are traded, or quoted, as applicable, on a national securities exchange, over the counter on the Nasdaq Stock Market, or through
the National Market System of the Nasdaq Stock Market (an "IPO"), provided that the Company's officers, directors and
greater than one percent (1%) equity interest holders are similarly restricted from selling their securities of the Company in
that period.

 

(f)          Registration
Under Securities Act of 1933, as amended. The Company agrees that the Warrant Interests shall have certain incidental or "Piggyback"
registration rights pursuant to and as set forth in the Company's Investors' Rights Agreement or similar agreement, or if there
is no such agreement in existence, then such incidental or "Piggyback" registration rights as are customary in the venture
capital industry. The provisions set forth in the Company's Investors' Rights Agreement or similar agreement relating to the above
in effect as of the issue date may not be amended, modified or waived without the prior written consent of Holder unless such amendment,
modification, or waiver affects the rights associated with the Warrant Interests in the same manner as such amendment, modification
or waiver affects the rights associated with all other interests of the same series and class as the Warrant Interests granted
to Holder.

 

     7

     

    

 

9.           University
Put Option. Subject to the terms and conditions of this Section 10, at any time commencing on the date that is sixty (60) days
prior to the end of the Exercise Period, University as Holder may notify the Company that University desires to have the Company
repurchase the Warrant at a price equal to the aggregate Fair Market Value of the Warrant Interests minus the aggregate Exercise
Price of the Warrant Interests. In the event that, upon the expiration
of the Exercise Period, the Fair Market Value of one Interest of the Company is greater than the Exercise Price in effect on such
date, then regardless of the failure of University to notify the Company of its election pursuant to the preceding sentence, the
Company shall automatically repurchase the Warrant at a price equal to the aggregate Fair Market Value of the Warrant Interests
minus the aggregate Exercise Price of the Warrant Interests. The Fair Market Value shall be determined in accordance with Section
3(c), provided, that if University disputes the Fair Market Value as determined in accordance with Section 3(c), then the Fair
Market Value shall be determined by an independent business valuation specialist mutually approved by the Company and University.
Neither the Company nor University shall have had a relationship with such independent business valuation specialist within the
immediately preceding three (3) year period. Such determination of the Fair Market Value shall be final and binding on the Company
and University, and the Company shall be obligated to repurchase the Warrant to the extent legally permissible under Arizona
law. The Company's purchase shall be finalized and payment made in cash to University no later than sixty (60) days after receipt
of the Fair Market Value determination.

 

10.    
     Miscellaneous.

 

(a)          Amendments.
This Warrant and any term hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the
party against which enforcement of such change, waiver, discharge or termination is sought.

 

(b)          Governing
Law. This Warrant shall be governed in all respects by the laws of the State of Arizona, without regard to the conflicts of
laws provisions thereof.

 

(c)          Information
Rights. So long as the Holder holds this Warrant and/or any of the Warrant Interests, the Company shall deliver to the Holder
(a) promptly after mailing, copies of all communiques to the members and holders of interests of the Company, (b) within one hundred
fifty (150) days after the end of each fiscal year of the Company, the annual financial statements of the Company certified by
independent public accountants of recognized standing, if such financial statements have been audited, (c) within forty-five (45)
days after the end of each of the first three quarters of each fiscal year, the Company's quarterly, unaudited financial statements
and (d) within thirty (30) days after the end of each month, a Company-prepared monthly financial statement of the Company.

 

(d)          Attorneys'
Fees. If any action at law or in equity is necessary to enforce or interpret the terms of this Warrant, the prevailing party
shall be entitled to reasonable attorneys' fees, costs, and disbursements in addition to any other relief to which such party may
be entitled.

 

(e)          Notices.

 

(i)          Whenever
the Exercise Price or number of Interests purchasable hereunder shall be adjusted pursuant to Section 7 hereof, the Company shall,
at its expense, compute such adjustment in accordance with the terms of the Warrant and prepare an accounting setting forth such
adjustment showing in detail the facts upon which the adjustment is based including the event requiring the adjustment, the amount
of the adjustment, the method by which such adjustment was calculated, and the Exercise Price and number of Interests purchasable
hereunder after giving effect to such adjustment. The Company will mail a copy of each such accounting to the Holder within ten
(10) days of such adjustment.

 

     8

     

    

 

(ii)         In
case:

 

1.          the
Company shall take a record of holders of its Interests (or other equity interests or securities receivable upon the exercise of
this Warrant) for the purpose of entitling them to receive from the Company any dividend or other distribution (whether in cash,
property, equity interests or other securities and whether or not a regular cash dividend), any right to subscribe for any equity
interests of any class or any other securities (or any interests or securities convertible into equity interests), or to receive
any other right,

 

2.          of
an offer to sell any of the Company's equity interests (or other securities convertible into such equity interests), other than
(a) pursuant to the Company's equity interest option or other compensatory plans, (b) in connection with commercial credit arrangements
or equipment financings, or (c) in connection with strategic transactions for purposes other than capital raising,

 

3.          of
any capital reorganization of the Company, any reclassification of the equity interests of the Company, any consolidation or merger
of the Company with or into another limited liability company (or other business entity), or any conveyance of all or substantially
all of the assets of the Company,

 

4.          of
any voluntary or involuntary dissolution, liquidation or winding- up of the Company, or

 

5.          of
any offer to holders of registration rights the opportunity to participate in an underwritten public offering of the Company's
securities for cash,

 

then in connection with each
such event, the Company shall give to Holder: (A) at least fifteen (15) days prior written notice of the date on which a record
will be taken for dividend, distribution, or subscription rights (and specifying the date on which the holders of Interests will
be entitled thereto) or for determining the right to vote, if any, in respect of the matters referred to in (3) and (4) above,
(B) in the case of matters referred to in (3) and (4) above, at least fifteen (15) days prior written notice of the date when the
same will take place (and specifying the date on which the holders of Interests will be entitled to exchange their Interests for
securities or other property deliverable upon the occurrence of such event); and (C) in the case of the matter referred to in (5)
above, the same notice as is given to the holders of such registration rights.

 

(iii)        Any
notice or other communication required or permitted to be given hereunder shall be in writing and shall be mailed by certified
mail, return receipt requested, or by Federal Express, Express Mail or similar overnight delivery or courier service or delivered
by facsimile transmission or email or personal delivery to whom it is to be given,

 

if to the Company:

President or CEO

Cancer Prevention Pharmaceuticals,
LLC

1708 W. Sunset Road

Tucson, Arizona 85704

 

if to the Holder:

Director

Office of Technology Transfer

University of Arizona

 

     9

     

    

 

University Services Building,
Room 204

888 North Euclid Avenue

Tucson, Arizona 85721

 

or in either
case, to such other address or facsimile number as the party shall have furnished in writing in accordance with the provisions
of this Section. Notice to the estate of any party shall be sufficient if addressed to the party as provided in this Section. Any
notice or other communication given by certified mail shall be deemed given at the time of certification thereof, except for a
notice changing a party address which shall be deemed given at the time of receipt thereof. Any notice given by other means permitted
by this Section shall be deemed given at the time of receipt thereof.

 

(f)          The
terms "Interests" and "Warrant Interests" shall also include any securities that the Holder has received upon
conversion of such Interests or Warrant Interests or any securities received by the Holder in exchange for such Interests or Warrant
Interests (for example, upon conversion of the Company into a corporation from a limited liability company).

 

[Signature Page Follows]

 

     10

     

    

 

IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized.

 

	Dated: ______________, 20____	CANCER PREVENTION PHARMACEUTICALS, LLC
	 	 	 
	 	By:	/s/ Eugene W. Gerner
	 	Name:	Eugene W. Gerner
	 	Title:	Co-founder and Co-Manager

 

	 	THE ARIZONA BOARD OF REGENTS, on behalf of THE UNIVERSITY OF ARIZONA
	 	 
	 	/s/ Patrick L. Jones, Director
	 	Patrick L. Jones, Director
	 	Office of Technology Transfer
	 	University of Arizona

 

[Signature Page to Limited Liability
Company Interest Warrant]

 

     

     

    

 

EXHIBIT A

Company Equity Interests

 

[Define the type and quantity
of equity interests of the Company to be purchased and the exercise price.]

 

1.          "Interests"
means the following ownership interest in the Company: Class A Units of Company as defined in the Operating Agreement of the Company.

 

2.          The
aggregate number of Interests to which this Warrant applies (defined as the "Warrant Interests") is: Three Hundred Thousand
(300,000).

 

3.          The
exercise price for a single Interest is $0.10 and the aggregate exercise price for all of the Warrant Interests is Thirty Thousand
Dollars ($30,000).

 

     

     

    

 

EXHIBIT B

NOTICE OF EXERCISE

 

To: Cancer Prevention Pharmaceuticals, LLC

 

(1)         The
undersigned hereby elects to purchase ____________ Interests of Cancer Prevention Pharmaceuticals, LLC, a limited liability
company organized under the laws of [Insert jurisdiction of organization], pursuant to the terms of the attached Warrant,
and tenders herewith payment of the purchase price for such equity interests in full.

 

(2)         In
exercising this Warrant, the undersigned hereby confirms and acknowledges that the Company's Interests are being acquired solely
for the account of the undersigned and not as a nominee for any other party, for investment, and that the undersigned shall not
offer, sell or otherwise dispose of any such Interests except under circumstances that will not result in a violation of the Securities
Act of 1933, as amended, applicable state securities laws, and that the undersigned will continue to be bound by Section 9(c) of
the Warrant after exercise of this Warrant.

 

(3)         Please
issue a certificate or certificates representing such Interests in the name of the undersigned or in such other name as is specified
below:

 

 

	 	 	 
	 	 	(Name)
	 	 	 
	 	 	 
	(Date)	 	(Name)

 

(4)         Please
issue a new Warrant for the unexercised portion of the attached Warrant in the name of the undersigned or in such other name as
is specified below:

 

	 	 	 
	 	 	(Name)
	 	 	 
	(Date)	 	(Signature)

 

	☐	Check here if this Notice is for a "net exercise" pursuant to Section 3(b) of this Warrant.

 

     

     

    

 

EXHIBIT C

ASSIGNMENT FORM

 

FOR VALUE
RECEIVED, the undersigned registered owner of this Warrant hereby sells, assigns and transfers unto the assignee named below ("Assignee")
all of the rights of the undersigned under this Warrant, with respect to the number of Interests set forth below:

 

	Name of Assignee	 	Address	 	No. of

Warrant Interests
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 

 

and
does hereby irrevocably constitute and appoint Attorney____________________ to make such transfer on the books of Cancer
Prevention Pharmaceuticals, LLC, maintained for the purpose, with full power of substitution
in the premises.

 

The undersigned
also represents that, by assignment hereof, the Assignee acknowledges that this Warrant and the equity interests to be issued upon
exercise hereof or conversion thereof are being acquired for investment and that the Assignee shall not offer, sell or otherwise
dispose of this Warrant or equity interests to be issued upon exercise hereof or conversion thereof except under circumstances
that will not result in a violation of the Securities Act of 1933, as amended, or applicable state securities laws. Further, the
Assignee acknowledges that, upon exercise of this Warrant, the Assignee shall, if requested by the Company, confirm in writing,
in a form satisfactory to the Company, that the equity interests so purchased are being acquired for investment and not with a
view toward distribution or resale. The Assignee further acknowledges and agrees that it is bound by all of the Warrant, including
the provisions of Section 9(c) thereof.

 

	 	 	 
	(Date)	 	 
	 	 	 
	 	 	Signature of Holder
	 	 	 
	 	 	 
	 	 	Signature of Assignee

 

     

     

    

 

		
        

        Cancer Prevention Pharmaceuticals

        1760 E. River Road, Suite 250

        Tucson, AZ 85718

        Phone: 520-908-7774

 

 

 

January 12, 2010

 

 

Patrick L. Jones

The University of Arizona

Office of Technology Transfer

888 North Euclid Ave., Room
204

Tucson, Arizona 85721-0158

 

Dear Mr. Jones:

 

The purpose
of this letter is to describe the effects of the proposed conversion of Cancer Prevention Pharmaceuticals, LLC, an Arizona limited
liability company into Cancer Prevention Pharmaceuticals, Inc., a Delaware corporation upon the equity holders of the LLC (including
the University (as defined below)). If you concur with the conclusions contained herein, we would appreciate your so acknowledging
by signing in the space provided below on the enclosed copy of this letter.

 

The Arizona
Board of Regents, on behalf of The University of Arizona (“University”) is the holder of Limited Liability Company
Interest Warrant to Purchase Interests of Cancer Prevention Pharmaceuticals, LLC No. W-CPP-1 dated May 28, 2009 (the “Warrant”)
issued pursuant to the Warrant Purchase Agreement between the LLC and University dated May 28, 2009 (the “Purchase Agreement”).

 

The Warrant
entitles the University to purchase 300,000 Class A Units (as defined in the Operating Agreement of Cancer Prevention Pharmaceuticals,
LLC, an Arizona limited liability company (the “LLC”)) at an exercise price of ten cents ($0.10) each.

 

At the time
of the issuance of the Warrant, it was contemplated that, at some time in the future, the LLC would be converted from a limited
liability company into a corporation. In anticipation of such conversion, Section 10(f) of the Warrant provides:

 

The terms “Interests”
and “Warrant Interests” shall also include any securities that the Holder has received upon conversion of such Interests
or Warrant Interests or any securities received by the Holder in exchange for such Interests or Warrant Interests (for example,
upon conversion of the Company into a corporation from a limited liability company). 

 

It is anticipated
that such conversion (“Conversion”) will take place effective as of December 31, 2009 and the Members of the LLC will
contribute their Units (as defined in the Operating Agreement) to Cancer Prevention Pharmaceuticals, Inc., a Delaware corporation
(the “Corporation”) in exchange for the Corporation’s $0.001 per
share par value Common Stock (“Common Stock”) at a conversion rate of .176991 shares of Common Stock for each Unit.

 

 

 

 

     

     

    

 

 

		
        

        Cancer Prevention Pharmaceuticals

        1760 E. River Road, Suite 250

        Tucson, AZ 85718

        Phone: 520-908-7774

 

 

 

Pursuant
to Section 10(f) of the Warrant, as a result of the Conversion, the Warrant will become the right by the University to purchase
53,097 shares of Common Stock at an exercise price of $0.565 per share.

 

Attached
hereto as Exhibit A is a Proforma Capitalization Table showing the capital structure of the LLC prior to the Conversion and that
of the Corporation after the Conversion.

 

With the
exception of the modification of the number and type of security purchasable pursuant to the Warrant and the exercise price thereof,
all remaining terms and conditions of the Warrant shall continue in full force and effect.

 

	 	CANCER PREVENTION
	 	PHARMACEUTICALS, LLC
	 	 
	 	By:     /s/ Eugene W. Gerner                                   
	 	           Eugene W. Gerner
	 	Title:  Co-founder and Co-Manager
	 	 
	 	 
	 	CANCER PREVENTION
	 	PHARMACEUTICALS, INC.
	 	 
	 	By:     /s/ Jeff Jacob                                                   
	 	           Jeff Jacob
	 	Title:  Chief Executive Officer
	 	 
	 	 
	 	Acknowledged and Confirmed:
	 	THE UNIVERSITY BOARD OF REGENTS,
	 	on behalf of THE UNIVERSITY OF ARIZONA
	 	 
	 	/s/ Patrick L. Jones                                                   
	 	Patrick L. Jones, Director
	 	Office of Technology Transfer
	 	University of Arizona

 

 

 

 

    	 

    	 

    

 

		
        

        Cancer Prevention Pharmaceuticals

        1760 E. River Road, Suite 250

        Tucson, AZ 85718

        Phone: 520-908-7774

 

 

 

	CANCER PREVENTION PHARMACEUTICALS
	
        PRE- AND POST-

        CONVERSION CAP

        TABLE

 

	 	 	(fully-diluted)	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	EQUITY HOLDER	 	# UNITS	 	 	% OWNERSHIP	 	 	# SHARES	 	 	% OWNERSHIP	 
	Gerner	 	 	2,000,000	 	 	 	33.61	%	 	 	353,982	 	 	 	33.61	%
	Meyskens	 	 	2,000,000	 	 	 	33.61	%	 	 	353,982	 	 	 	33.61	%
	Tierney	 	 	1,000,000	 	 	 	16.81	%	 	 	176,991	 	 	 	16.81	%
	Jacob (A Units)	 	 	200,000	 	 	 	3.36	%	 	 	35,398	 	 	 	3.36	%
	Jacob (B Units)	 	 	450,000	 	 	 	7.56	%	 	 	79,646	 	 	 	7.56	%
	UA (Warrant)*	 	 	300,000	 	 	 	5.04	%	 	 	53,097	 	 	 	5.04	%
	 	 	 	5,950,000	 	 	 	 	 	 	 	1,053,096	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Conversion Ratio - .176991 
shares/unit	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Warrant Exercise Price:	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Per Unit:	 		$0.10	 	 	 	 	 	 	 	 	 	 	 	 	 
	Per Share:	 		$0.565Exhibit 4.9

 

STOCKHOLDERS AGREEMENT

 

THIS STOCKHOLDERS AGREEMENT
(the “Agreement”) is made effective as of December 31, 2009, by and among the individuals listed on the signature page
and Exhibit A, and such other persons who shall become parties pursuant to the terms hereof (collectively, the “Stockholders”;
individually, a “Stockholder”) and Cancer Prevention Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”).

 

RECITALS

 

The Stockholders and
the Corporation desire for their mutual benefit and protection to enter into an agreement for the continuity and stability of the
business and policies of the Corporation, and to that end, the Corporation and the Stockholders hereby set forth their agreement
with respect to the Stockholder Shares (as defined below) that are owned or may be acquired by the Stockholders.

 

NOW, THEREFORE, in
consideration of the mutual covenants contained herein, and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Stockholders and the Corporation hereby agree as follows:

 

Section 1.            Definitions.

 

As used in this Agreement,
the following terms shall have the meanings ascribed to them below:

 

“Agreement”
means this Stockholders Agreement.

 

“Board”
means, with respect to the Corporation, the board of directors of the Corporation.

 

“Common Stock”
means, collectively the Common Stock, and any other class of capital stock of the Corporation authorized after the date hereof,
that is not entitled to at least a fixed sum or stated value in respect of the rights of the holders thereof to participate in
dividends or in the distribution of assets upon any liquidation, dissolution or winding up of the Corporation.

 

“Corporation”
has the meaning set forth in the caption to this Agreement.

 

“Convertible
Securities” means any stock or securities convertible, directly or indirectly, into or exchangeable for Common Stock.

 

“Equity Securities”
means all shares of capital stock of the Corporation, all securities convertible into or exchangeable for shares of capital stock
of the Corporation, and all options, warrants, and other rights to purchase or otherwise acquire from the Corporation shares of
such capital stock, or securities convertible into or exchangeable for shares of such capital stock.

  

     

     

    

  

“Permitted
Transferee” shall mean and include (i) another Stockholder, (i) a Stockholder’s spouse, (iii) a Stockholder’s
lineal descendants or ancestors (and their spouses), (iv) a trustee of a trust for the principal benefit of a Stockholder or a
person described in (ii) or (iii), (v) upon death of the Stockholder or of a Permitted Transferee of a Stockholder, his or her
respective heirs, administrators and executors, or (vi) an entity a majority of the outstanding equity interests of which are owned
by such Stockholder or Permitted Transferee.

 

“Person”
shall be construed broadly and shall include, without limitation, an individual, a partnership, an investment fund, a limited liability
company, a corporation, an association, a joint stock company, a trust, a joint venture, an unincorporated organization and a governmental
entity or any department, agency or political subdivision thereof.

 

“Public Offering”
means, with respect to any Person, the sale, in an underwritten public offering registered under the Securities Act, of shares
of the capital stock of such Person.

 

“Qualified
Public Offering” shall mean an initial Public Offering of Common Stock underwritten on a firm commitment basis which
results in aggregate net cash proceeds to the Corporation of not less than $30,000,000 and based upon a valuation of the Corporation
(prior to the consummation of such transaction) of at least $60,000,000.

 

“Securities
Act” means the Securities Act of 1933, as the same may be amended or supplemented from time to time, or any successor
statute, and the rules and regulations thereunder, as the same are from time to time in effect.

 

“Stockholder”
means any Person (whether as of the date hereof or hereafter) who executes this Agreement as a Stockholder, or any other person
which or who has executed a Stockholder Joinder.

 

“Stockholder
Joinder” means a joinder agreement, substantially in the form of Exhibit B hereto, by which a Person may have become
or may in the future become a Stockholder on or after the date hereof.

 

“Stockholder
Shares” means (i) any Common Stock purchased or otherwise acquired by any Stockholder, (ii) any Common Stock issued upon
the exercise or conversion of any Convertible Securities, and (iii) any Equity Securities issued or issuable directly or indirectly
with respect to the Common Stock referred to in clause (i) and clause (ii) above by way of stock dividend or stock split or in
connection with a combination of shares, recapitalization, merger, consolidation or other reorganization. For purposes of this
Agreement, holders of any portion of any Convertible Securities shall be deemed to be holders of Stockholder Shares issuable upon
exercise of such Convertible Securities and therefore shall be subject to the provisions and restrictions of this Agreement. As
to any particular shares constituting Stockholder Shares, such shares will cease to be Stockholder Shares when they have been effectively
registered under the Securities Act and disposed of in accordance with the registration statement covering them.

 

“Termination
Date” means the date of consummation of any Qualified Public Offering or liquidation of the Corporation.

 

    	 	 2	 

     

    

 

 

 

“Transfer”
means the sale, transfer, assignment, pledge or other disposal (whether with or without consideration and whether voluntarily or
involuntarily or by operation of law) of any interest in any Stockholder Shares.

 

Section 2.           Limitations
on Transfers

 

No Transfer of any
Stockholder Shares before the Termination Date shall become effective unless and until the transferee executes and delivers to
the Corporation a counterpart to this Agreement in the form of a Stockholder Joinder, agreeing to be treated in the same manner
as the transferring Stockholder. Upon such Transfer and such execution and delivery, the transferee shall be bound by, and entitled
to the benefits of, this Agreement with respect to the transferred Stockholder Shares.

 

Section 3.           Transfer
of Stockholder Shares

 

3.1         Right
of First Refusal. In addition to any requirements set forth below, Transfers of Stockholder Shares will be subject to a right
of first refusal as follows: before any Stockholder Shares may be sold or transferred (including transfer by operation of law),
the holder of such Stockholder Shares (“Selling Stockholder”) shall first offer such Stockholder Shares to the Corporation
and the other Stockholders in accordance with the following terms and conditions:

 

A.        The
Selling Stockholder shall deliver a notice (the “Notice”) to the Board and the other Stockholders stating (i) its bona
fide intention to sell or transfer such Stockholder Shares; (ii) the price for which its proposes to sell or transfer such Stockholder
Shares; and (iii) the name of the proposed purchaser or transferee. A copy of a written offer from the proposed purchaser or transferee
shall be attached to the Notice.

 

B.        Within
thirty (30) days after receipt of the Notice, the Board may elect to cause the Corporation to purchase all or any portion of the
Stockholder Shares to which the Notice refers on the same terms and conditions specified in the Notice.

 

C.        If
the Corporation does not elect to purchase the Stockholder Shares in question, then within sixty (60) days after receipt of the
Notice, the other Stockholders may elect to purchase all or any portion of the Stockholder Shares to which the Notice refers, on
the same terms and conditions specified in the Notice. In the event that more than one Stockholder wishes to purchase the Stockholder
Shares being offered, each of the Stockholders desiring to purchase the Stockholder Shares shall be entitled to purchase a proportionate
share of the Stockholder Shares in the same ratio as the number of shares of Common Stock owned by each of them bears to the number
of shares of Common Stock owned by all of them.

 

D.        If
all of the Stockholder Shares to which the Notice refers are not purchased as provided in Paragraphs B and C immediately above,
the Selling Stockholder may sell the Stockholder Shares that were not purchased to the person named in the Notice at the price
specified in the Notice or at a higher price, provided that:

 

    	 	 3	 

     

    

 

 

 

(1)         such
sale or transfer is consummated within ninety (90) days of the date of the Notice;

 

(2)         any
such sale is in accordance with all the terms and conditions hereof;

 

(3)         the
Stockholder Shares sold pursuant hereto will remain subject to the terms hereof to the same extent as if such Stockholder Shares
had not been sold by the Selling Stockholder; and

 

(4)         Unless
waived by the Corporation, the Selling Stockholder shall deliver to the Corporation an opinion of counsel, in form acceptable to
counsel to the Corporation that:

 

(a)       The
proposed Transfer of the Stockholder Shares will comply with all federal and state laws and regulations, including the Securities
Act; and

 

(b)       The
proposed Transfer will not affect the availability to the Corporation of the exemption from registration of the Stockholder Shares
provided by Regulation D promulgated by the Securities and Exchange Commission under Section 4(2) of the Securities Act or any
similar exemption from registration under federal law or any applicable state blue sky laws.

 

(c)       The
proposed purchaser or transferee shall deliver to the Corporation an investment letter, in form acceptable to the Board, stating
that such proposed purchaser or transferee is acquiring the Stockholder Shares in the Corporation for investment purposes only
and not for the purpose of reselling or otherwise distributing such Stockholder Shares to the public.

 

E.         An
offer shall be accepted by giving notice of acceptance to the party giving notice of the offer. If acceptance is by the Corporation,
notice of acceptance shall be given concurrently to the Stockholders. If the acceptance is by one or more of the Stockholders other
than the Selling Stockholder, notice of the acceptance shall be given concurrently to the Corporation and to all Stockholders.

 

F.         Reimbursement
of Expenses. The Selling Stockholder shall reimburse the Corporation for all expenses, including, without limitation, legal
fees, connected with such Transfer.

 

3.2        Permitted
Transferee. The provisions of Section 3.1 shall not apply to a proposed Transfer to a Permitted Transferee.

 

Section 4.           Involuntary
Transfer

 

If Stockholder Shares
are to be purchased pursuant to an offer that is the result of a proposed transfer pursuant to a judicial or private sale under
writ of execution or foreclosure of a security in the Stockholder Shares, the price to be paid shall be the total amount required
to redeem the Stockholder Shares and discharge or satisfy the judicial process or security agreement. If the Corporation or the
Stockholders purchase the Stockholder Shares under the circumstances described in this subsection, the Selling Stockholder shall
have a period of sixty (60) days after such purchase within which to redeem the shares by repayment to the Corporation or the Stockholders
of the amount paid for the Stockholder Shares plus any other costs, including attorney’s fees, incurred by the Corporation
or the Stockholders in the making of such purchase, plus Stockholder Shares on the amount paid and costs incurred at the rate of
ten percent (10%) per annum from the date of payment.

  

    	 	 4	 

     

    

  

Section 5.           Additional
Restrictions on Transfer of Stockholder Shares

 

5.1         Legend.
The certificates representing the Stockholder Shares shall bear a legend substantially in the following form:

 

THE SECURITIES REPRESENTED BY
THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, THE ARIZONA SECURITIES ACT OR THE SECURITIES LAWS OF
ANY OTHER STATE OR JURISDICTION. THEY MAY NOT BE PURCHASED WITH A VIEW FOR DISTRIBUTION OR RESALE, AND MAY ONLY BE OFFERED, SOLD,
MORTGAGED, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED IN COMPLIANCE WITH EITHER AN EFFECTIVE REGISTRATION STATEMENT FOR SUCH
SECURITY UNDER THE SECURITIES ACT OF 1933 OR ANY APPLICABLE STATE SECURITIES ACT, OR AN OPINION OF COUNSEL FOR THE CORPORATION
THAT REGISTRATION IS NOT REQUIRED UNDER SUCH ACT OR THE LAWS OF ANY OTHER JURISDICTION. THIS CERTIFICATE SHALL BE REGISTERED ON
THE BOOKS OF THE CORPORATION WITH “STOP TRANSFER” INSTRUCTIONS, THUS PRECLUDING FUTURE UNREGISTERED TRANSFER.

 

THE HOLDER OF THESE SECURITIES
IS SUBJECT TO A STOCKHOLDERS AGREEMENT DATED DECEMBER 31, 2009 BETWEEN THE CORPORATION AND CERTAIN STOCKHOLDERS OF THE CORPORATION
AND, EXCEPT AS PROVIDED IN SUCH AGREEMENT, THE TRANSFEREE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE MUST AGREE TO BE BOUND
BY THE TERMS OF SUCH STOCKHOLDERS AGREEMENT AS A CONDITION OF TRANSFER.

 

5.2         Transfers
in Violation of Agreement. Any Transfer or attempted Transfer of any Stockholder Shares in violation of any provision of this
Agreement shall be void, and the Corporation shall not record such Transfer on its books or treat any purported transferee of such
Stockholder Shares as the owner of such Stockholder Shares for any purpose.

 

5.3         Pledges.
Notwithstanding any provision in this Agreement to the contrary, no holder of Stockholder Shares may pledge any Stockholder Shares
on or after the date hereof.

 

 

    	 	 5	 

     

    

  

Section 6.           Binding
Effect; Joinders; Additional Shares

 

6.1        Any
transferee of Stockholder Shares from a Stockholder (other than the Corporation or another Stockholder) shall, as a condition to
such Transfer, be deemed a Stockholder for purposes of this Agreement and be bound by and subject to the terms and provisions of
this Agreement applicable to Stockholders, and if not already a signatory to this Agreement as a Stockholder, such Person shall
execute and deliver to the Corporation a Stockholder Joinder.

 

6.2        In
the event additional Stockholder Shares are issued by the Corporation to a Stockholder at any time during the term of this Agreement,
such additional Stockholder Shares shall, as a condition to such issuance, be deemed subject to the terms and provisions of this
Agreement.

 

Section 7.           No
Conflicting Agreements

 

No Stockholder shall
enter into any stockholder agreements or arrangements of any kind with any Person with respect to any Stockholder Shares on terms
inconsistent with the provisions of this Agreement (whether or not such agreements or arrangements are with other Stockholders
or with Persons that are not parties to this Agreement), including, but not limited to, agreements or arrangements with respect
to the acquisition or disposition of Stockholder Shares in a manner that is inconsistent with this Agreement.

 

Section 8.           Further
Assurances

 

Each party hereto shall
do and perform or cause to be done and performed all such further acts and things and shall execute and deliver all such other
agreements, certificates, instruments and documents as any other party hereto reasonably may request in order to carry out the
provisions of this Agreement and the consummation of the transactions contemplated hereby.

 

Section 9.           Termination

 

9.1        All
of the provisions of this Agreement shall terminate and, except as otherwise expressly provided herein, shall be of no further
force or effect and shall not be binding upon any party hereto, upon the first to occur of (A) the consummation of a Qualified
Public Offering and (B) the approval of such termination by the Corporation and the holders of seventy-five percent (75%) of the
Stockholder Shares.

 

9.2        As
to any particular Stockholder, this Agreement shall no longer be binding or of further force or effect as to such Stockholder,
except as otherwise expressly provided herein, as of the date such Stockholder has transferred all such Stockholder's Stockholder
Shares and each transferee of such Stockholder Shares shall have become a party hereto; provided, however, that no such termination
shall be effective if such Stockholder is in breach of this Agreement immediately before or after giving effect to such Transfer(s).

 

    	 	 6	 

     

    

 

Section 10.           General
Provisions

 

10.1        Amendment;
Waiver and Release. Except as otherwise provided herein, no modification, amendment or waiver of any provision of this Agreement
shall be effective unless such modification, amendment or waiver is approved in writing by all of the Stockholders of the Corporation.
The failure of any party to enforce any of the provisions of this Agreement shall in no way be construed as a waiver of such provisions
and shall not affect the right of such party thereafter to enforce each and every provision of this Agreement in accordance with
its terms.

 

Notwithstanding the above,
amendments may be made to this Agreement from time to time by the Board without the consent of the Stockholders only to cure any
ambiguity or correct or supplement any provision hereunder which may be inconsistent with any other provision hereunder provided
that such amendment is for the benefit of the Stockholders.

 

10.2        Severability.
It is the desire and intent of the parties hereto that the provisions of this Agreement be enforced to the fullest extent permissible
under the laws and public policies applied in each jurisdiction in which enforcement is sought. Accordingly, if any particular
provision of this Agreement shall be adjudicated by a court of competent jurisdiction to be invalid, prohibited or unenforceable
for any reason, such provision, as to such jurisdiction, shall be ineffective, without invalidating the remaining provisions of
this Agreement or affecting the validity or enforceability of this Agreement or affecting the validity or enforceability of such
provision in any other jurisdiction. Notwithstanding the foregoing, if such provision could be more narrowly drawn so as not to
be invalid, prohibited or unenforceable in such jurisdiction, it shall, as to such jurisdiction, be so narrowly drawn, without
invalidating the remaining provisions of this Agreement or affecting the validity or enforceability of such provision in any other
jurisdiction.

 

10.3        Entire
Agreement.    Except as otherwise expressly set forth herein, this document embodies the complete agreement and understanding
among the parties hereto with respect to the subject matter hereof and supersedes and preempts any prior understandings, agreements
or representations by or among the parties, written or oral, which may have related to the subject matter hereof in any way.

 

10.4        Successors
and Assigns.    Except as otherwise provided herein, this Agreement shall bind and inure to the benefit of and be
enforceable by the Corporation and, so long as Stockholder Shares are held by such Person, each Person which or who was a Stockholder
on the date hereof and each Person which or who was or in the future becomes a Stockholder, subsequent to that date, shall not
assign or transfer Stockholder Shares unless such Stockholder shall comply with this Agreement. None of the provisions hereof shall
create, or be construed or deemed to create, any right of employment in favor of any Person by the Corporation or any of its Subsidiaries.
This Agreement is not intended to create any third party beneficiaries.

 

10.5        Counterparts. 
This Agreement may be executed in separate counterparts each of which shall be an original and all of which taken together shall
constitute one and the same agreement.

 

    	 	 7	 

     

    

 

10.6        Remedies.
The Corporation and the Stockholders shall be entitled to enforce their rights under this Agreement specifically to recover damages
by reason of any breach of any provision of this Agreement and to exercise all other rights existing in their favor. The Corporation
and the Stockholders agree and acknowledge that money damages may not be an adequate remedy for any breach of the provisions of
this Agreement and that the Corporation and any Stockholder may in its sole discretion apply to any court of law or equity of competent
jurisdiction for specific performance and/or injunctive relief (without posting a bond or other security) in order to enforce or
prevent any violation of the provisions of this Agreement.

 

10.7        Notices.
All notices, requests, demands, claims, and other communications hereunder shall be in writing and shall be deemed to have been
duly given if delivered personally, by facsimile, sent by nationally recognized overnight courier or mailed by registered or certified
mail (return receipt requested), postage prepaid, to the parties at the following addresses (or at such other address for a party
as shall be specified by like notice):

 

(i)       If
to the Corporation, to:

Cancer Prevention Pharmaceuticals,
Inc.

1760 E. River
Road, Suite 250

Tucson, AZ 
85718

 

with a copy to:

Hecker & Muehlebach, PLLC

Rockwell Building

405 West
Franklin Street

Tucson, AZ
85701-8209

Attention: Lawrence M. Hecker

Telephone: (520) 798-3803

Fax: (520) 620-0405

 

(ii)     If
to a Stockholder set forth on Schedule A hereto, to the related address or facsimile number set forth on Schedule A hereto.

 

(iii)     If
to a Stockholder not set forth on Schedule A hereto, to the related address or facsimile number set forth in the Stockholder Joinder
executed and delivered by such Stockholder to the Corporation.

 

All such notices and
other communications shall be deemed to have been given and received (a) in the case of personal delivery or delivery by facsimile,
on the date of such delivery, (b) in the case of delivery by nationally recognized overnight courier, on the third (3rd)
business day following such dispatch and (c) in the case of mailing, on the seventh (7th) business day following such
mailing.

 

    	 	 8	 

     

    

 

10.8        GOVERNING
LAW.    THIS AGREEMENT WILL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE DOMESTIC LAWS OF THE STATE OF ARIZONA,
WITHOUT GIVING EFFECT TO ANY CHOICE OF LAW OR CONFLICTING PROVISION OR RULE (WHETHER OF THE STATE OF ARIZONA, OR ANY OTHER JURISDICTION)
THAT WOULD CAUSE THE LAWS OF ANY JURISDICTION OTHER THAN THE STATE OF ARIZONA TO BE APPLIED, EXCEPT TO THE EXTENT THAT THIS AGREEMENT
RELATES TO THE INTERNAL AFFAIRS OF THE CORPORATION, WHICH SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE
STATE OF ARIZONA WITHOUT GIVING EFFECT TO ANY CHOICE OF LAW OR CONFLICTING PROVISION OR RULE (WHETHER OF THE STATE OF ARIZONA OR
ANY OTHER JURISDICTION) THAT WOULD CAUSE THE LAWS OF ANY JURISDICTION OTHER THAN THE STATE OF ARIZONA TO BE APPLIED TO SUCH MATTERS.
IN FURTHERANCE OF THE FOREGOING, THE INTERNAL LAW OF THE STATE OF ARIZONA WILL CONTROL THE INTERPRETATION AND CONSTRUCTION OF THIS
AGREEMENT, EVEN IF UNDER SUCH JURISDICTION'S CHOICE OF LAW OR CONFLICT OF LAW ANALYSIS, THE SUBSTANTIVE LAW OF SOME OTHER JURISDICTION
WOULD ORDINARILY APPLY.

 

10.9        Descriptive
Headings. The descriptive headings of this Agreement are inserted for convenience only and do not constitute a part of this
Agreement.

 

10.10        Construction
  Where specific language is used to clarify by example a general statement contained herein, such specific language shall
not be deemed to modify, limit or restrict in any manner the construction of the general statement to which it relates. The language
used in this Agreement shall be deemed to be the language chosen by the parties to express their mutual intent, and no rule of
strict construction shall be applied against any party.

 

10.11       Waiver
of Jury Trial. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR
COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT.

 

10.12       Nouns
and Pronouns. Whenever the context may require, any pronouns used herein shall include the corresponding masculine, feminine
or neuter forms, and the singular form of nouns and pronouns shall include the plural and vice-versa.

 

IN WITNESS WHEREOF,
the parties hereto have executed this Stockholders Agreement on the day and year first above written.

 

[signature page follows]

 

    	 	 9	 

     

    

 

[signature page to Cancer Prevention
Pharmaceuticals Stockholders Agreement

of December 31, 2009]

 

	 	Cancer Prevention Pharmaceuticals, Inc.
	 	 	 
	 	By:	/s/ Jeffrey Jacob
	 	 	 
	 	Its:	CEO

 

Stockholders:

 

	Meyskens Pharmaceutical Investors, LLC	 	Gerner Pharmaceutical Investors, LLC,
	 	 	 
	/s/ Frank Meyskens	 	/s/ Eugene Gerner
	Frank Meyskens	 	Eugene Gerner
	Co-Founder	 	 
	Title	 	Title
	 	 	 
	 	 	 
	The Tierney Family Trust	 	 
	 	 	 
	/s/ Thomas T. Tierney	 	/s/ Jeffrey Jacob
	Thomas T. Tierney, Trustee	 	Jeffrey Jacob
	 	 	 
	/s/
    Elizabeth C. Tierney	 	/s/
    Deborah Jacob
	Elizabeth C. Tierney, Trustee	 	Spouse

 

    	 	 10	 

     

    

 

EXHIBIT
A

 

STOCKHOLDERS

 

	1.	Meyskens Pharmaceutical Investors, LLC, an Arizona limited liability company
	2.	Gerner Pharmaceutical Investors, LLC, an Arizona limited liability company
	3.	The Tierney Family Trust, Thomas T. or Elizabeth C. Tierney as Trustees, (“Tierney”)
	4.	Jeffrey Jacob (“Jacob”).

 

    	 	 11	 

     

    

 

EXHIBIT B

 

STOCKHOLDER JOINDER

 

By execution of this
Stockholder Joinder, the undersigned agrees to become a party to that certain Stockholders Agreement dated as of December 31, 2009
(as the same may be amended, supplemented or otherwise modified from time to time, the “Stockholders Agreement”), among
Cancer Prevention Pharmaceuticals, Inc., a Delaware corporation, and certain of its stockholders. The undersigned shall have all
the rights, and shall observe all the obligations, applicable to a Stockholder (as defined in the Stockholders Agreement).

 

	Name:  	 	 

 

 

	Address for Notices:	 	With copies to:
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 

 

	Signature:	 	 

 

	Date:	 	 

  

    	 	 12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}]]